RIG-I agonist therapy can enhance the activity of anti-cancer effector cells (e.g., cytotoxic T cells and NK cells) and block the activity of immunosuppressive cells (e.g., regulatory T cells and myeloid-derived suppressor cells [MDSCs]), successfully induce the killing of tumor cells, and regulate the TME [25]. The gene discussed is RIGI; the disease is cancer.